Abstract
Objective: Platinum-based chemotherapy is widely used for a variety of cancers including serous ovarian cancer (SOC). However, platinum resistance is a major contributor to the high mortality of SOC patients. Accumulated evidence has implied that DNA methylation may serve as a potential biomarker for chemotherapy-resistant phenotypic screening; however, the pattern underlying platinum resistance remains unclear.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
